TY - JOUR T1 - Review: antiplatelet agents (particularly aspirin) reduce the incidence of pre-eclampsia in women at risk JF - Evidence Based Medicine JO - Evid Based Med SP - 49 LP - 49 DO - 10.1136/ebm.10.2.49 VL - 10 IS - 2 A2 - , Y1 - 2005/04/01 UR - http://ebm.bmj.com/content/10/2/49.abstract N2 - Duley L, Henderson-Smart DJ, Knight M, et al. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2004;(1):CD004659. 
 
 Q In pregnant women at risk, is prophylactic use of antiplatelet agents (such as aspirin and dipyridamole) effective for preventing or delaying the development of pre-eclampsia as well as other related maternal and child outcomes? Clinical impact ratings FP/GP/Obstetrics ★★★★★★☆ Obstetrics ★★★★★★☆ Data sources: the Cochrane Pregnancy and Childbirth Group trials register (September 2003), the Cochrane Central Register of Controlled Trials (Cochrane Library, Issue 2, 2003), EMBASE/Excerpta Medica (1994–2003), and congress proceedings of the International and European Societies for the Study of Hypertension in Pregnancy (up to 2002). Study selection and assessment: randomised controlled trials (RCTs) that compared any antiplatelet agent (such as low dose aspirin or dipyridamole) with a control condition comprising placebo or no antiplatelet agent in pregnant women considered to be at risk of developing pre-eclampsia. Exclusion criteria included comparisons of 1 antiplatelet agent with another, and of antiplatelets with other interventions. Study quality was assessed … ER -